Risk Indicators of Sarcoidosis Evolution-Unified Protocol

Description

The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.

Conditions

Sarcoidosis, Pulmonary

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.

Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis

Risk Indicators of Sarcoidosis Evolution-Unified Protocol

Condition
Sarcoidosis, Pulmonary
Intervention / Treatment

-

Contacts and Locations

Baltimore

University of Maryland, Baltimore, Maryland, United States, 21201

Dallas

UT Southwestern, Dallas, Texas, United States, 75390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adults with a diagnosis of sarcoidosis over the age of 18
  • 2. Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization/chronic beryllium disease, mycobacterial, viral, and/or fungal infection
  • 1. Inability to tolerate study procedures as determined by the investigator
  • 2. Pregnant or breastfeeding
  • 3. Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases
  • 4. Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
  • 5. Hematocrit (Packed Cell Volume) \< 25%

Ages Eligible for Study

19 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Laura Koth, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2026-03-30